What RADL3 DFP Footnotes Reveal About GLP-1 and Digital Sales

The research question

> Analyze the financial footnotes and identify the main factors affecting revenue, margins, costs, and expenses. Highlight relevant changes, non-recurring effects, and management explanations for result variations.

This mirrors how equity researchers and AI agents structure DFP work: start from the face statements, then drill into footnotes for the narrative behind the numbers.

What the DFP footnotes showed

Revenue drivers

Consolidated revenue grew materially in 2025:

Three structural drivers stood out in the footnotes:

1. Store expansion — 330 new pharmacies added to the network.
2. Digital acceleration — online sales exceeded R$ 11 billion, nearly 30% of retail.
3. GLP-1 medications — weight-loss drugs (semaglutide class) contributed meaningful revenue with a distinct margin profile.

The GLP-1 margin paradox

Gross margin held around 27.2%, a modest decline despite revenue growth. Footnotes attributed the pressure to:

• Mix shift toward GLP-1 — high ticket, lower percentage margin
• Inventory losses — higher write-offs during the period
• AVP (present value adjustment) effects on lease-related items

EBITDA adjusted reached R$ 3.375 billion (7.1% margin), structurally stable after operational recovery in the second half of 2025. Management linked the pattern to a first-half recovery program, price/promotion investments, digital expansion, and logistics efficiency gains.

Financial expense deterioration

Net financial expenses of roughly R$ 820 million worsened the bottom line — driven by higher debt, AVP effects, and the interest-rate environment. This is the kind of detail that does not appear in a simple P/E screen but matters for credit and equity analysis.

Why this matters beyond the API

Market data APIs give you price, volume, and sometimes summarized financials. They rarely explain:

• How a new drug category (GLP-1) reshapes margin structure
• What percentage of revenue is already digital
• Whether margin compression is strategic (mix) or operational (inventory)

Automated footnote analysis over CVM DFP filings closes that gap. For pharmacy-sector research, RADL3's disclosure is a concrete template: growth can look healthy on revenue while margins tell a more nuanced story.

How to replicate this with apicvm

export APICVM_KEY='apicvm_...'
export APICVM_URL='https://apicvm.dev'

# Resolve RADL3
curl -H "Authorization: Bearer $APICVM_KEY" \
  "$APICVM_URL/v1/companies/resolve?query=RADL3&by=ticker"

# List 2025 DFP
curl -H "Authorization: Bearer $APICVM_KEY" \
  "$APICVM_URL/v1/documents?ticker=RADL3&type=DFP&year=2025"

# Request page-level text extraction (async callback)
curl -X POST -H "Authorization: Bearer $APICVM_KEY" \
  -H "Content-Type: application/json" \
  -d '{"documentId": "<id>", "callbackUrl": "https://your-server/callback"}' \
  "$APICVM_URL/v1/document-text-extractions"

Once text is indexed, prompt your agent or search pipeline with footnote-focused questions: revenue breakdown, segment mix, non-recurring items, debt and financial expenses.

import os, requests

BASE = os.environ["APICVM_URL"]
H = {"Authorization": f"Bearer {os.environ['APICVM_KEY']}"}

docs = requests.get(
    f"{BASE}/v1/documents",
    params={"ticker": "RADL3", "type": "DFP", "year": 2025},
    headers=H,
).json()

Methodology note

Findings above come from a completed Hold analysis over RADL3's 2025 DFP footnotes (analysis result derived from public CVM disclosure). This is research illustration, not investment advice. Verify numbers against the original filing before trading or publishing reports.

Current limitations

• apicvm returns page-level markdown, not pre-parsed footnote sections — your pipeline segments text.
• Footnotes are in Portuguese; plan translation or multilingual models for English-only workflows.
• DFP is annual; for interim updates, pair with ITR quarterly filings.

Next steps

• Extract DFP financial footnotes programmatically
• RADL3 CVM filings overview
• Read the API docs
• Get an API key

Related guides

• Monitor quarterly earnings with ITR
• What is DFP